Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes

Table 6

Results of multiple backward stepwise regression analysis with PCSK9 as dependent variable in group of patients according to statin treatment and according to presence of NAFLD.

Variables in the reduced model			se
On statins
PTX3 (ng/ml)	0.44	13.75	2.774	0.03	<0.001
apo A1 (mg/dl)	0.41	1.54	0.340	0.09	<0.001
apo B100 (mg/dl)	0.21	1.01	0.442	0.09	0.0254
No statins
PTX3 (ng/ml)	0.41	16.54	5.172	0.03	0.0026
apo C3 (μg/ml)	0.34	0.28	0.107	0.03	0.0121
NAFLD present
apo A1 (mg/dl)	0.33	1.06	0.285	0.09	0.0004
apo C3 (μg/dl)	0.26	0.19	0.068	0.24	0.0065
apo B100 (mg/dl)	0.25	0.87	0.321	0.20	0.0082
PTX3 (ng/ml)	0.21	10.89	4.866	0.19	0.0282
No NAFLD
PTX3 (ng/ml)	0.54	15.21	3.380	0.005	<0.001
apo B48 (ng/ml)	0.32	0.010	0.004	0.06	0.0136
apo A1 (mg/dl)	0.26	1.15	0.542	0.06	0.0408

: partial regression coefficient; : partial standardized regression coefficient; : partial correlation coefficient; se: standard error for regression coefficient; : partial determination coefficient.